Hope Medicine Announces First Patient Dosed in the Phase III Clinical Trial for Endometriosis

SHANGHAI, March 24, 2026 /PRNewswire/ -- Hope Medicine Inc., a science-driven, clinical-stage innovative biopharmaceutical company, announced that the first patient has been dosed in the Phase III clinical trial of HMI-115, its first-in-class monoclonal antibody with global rights, for the treatment of endometriosis. The dosing took place at the leading study site in China, Peking Union Medical College Hospital. This Phase III trial is a multicenter, randomized, double-blind, placebo-controlled study designed to confirm the safety and efficacy of HMI-115 in treating moderate-to-severe pain associated with endometriosis, with a treatment period of 24 weeks. HMI-115 is currently the first and only non-hormonal therapy globally to have entered Phase III clinical development.

Previously, HMI-115 was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe pain associated with endometriosis. Additionally, HMI-115 was granted the Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). These recognitions from global regulatory authorities were primarily based on the results from a previously completed global multicenter Phase II clinical trial for HMI-115 in endometriosis, which demonstrated that HMI-115 achieved statistically significant improvement in moderate-to-severe pain associated with endometriosis, with no significant impact on key female hormones and no menopausal side effects. These findings have been published in The Lancet Obstetrics, Gynaecology, & Women's Health. Furthermore, Hope Medicine was nominated as "Best Startup" for the prestigious Prix Galien Award.

Regarding this significant clinical milestone, Professor Xiao Ruiping, Founder of Hope Medicine, stated:"The initiation of the Phase III clinical trial for HMI-115 in endometriosis, marks a milestone achievement in our clinical development. Peking Union Medical College Hospital, as the leading site, is at the forefront of this Phase III study. Hope Medicine remains unwavering in its original commitment to bringing truly differentiated first-in-class medicines to patients worldwide."

Mr. Chen Xi, Chief Executive Officer of Hope Medicine, also commented:"The launch of the Phase III trial signifies that the global development of HMI-115 for endometriosis has entered its final stage. Women's health is a key focus area for Hope Medicine, and we will drive this trial with the best speed and quality to bring this innovative treatment to patients as soon as possible."

About Endometriosis

Endometriosis is a common gynecological disease characterized by the implantation of endometrial cells outside the uterine cavity, typically presenting as a chronic inflammatory response. The endometrium is the mucosal tissue lining the uterine cavity, which undergoes hormone-dependent changes during the menstrual cycle. Endometriosis is common in women of reproductive age, with symptoms including lower abdominal and pelvic pain, dysmenorrhea, painful intercourse, and infertility. Comprehensive literature reports indicate that approximately 10% of women of reproductive age globally are affected by endometriosis, about 190 million women worldwide; 20%-50% of women with infertility have endometriosis, and 71%-87% of women with chronic pelvic pain have endometriosis. Endometriosis is one of the leading causes of dysmenorrhea, infertility, and chronic pelvic pain. The disease often leads to decreased quality of life, affecting patients' sexual health, psychological well-being, and social behavior. Globally, the disease represents a potential market size of approximately US$200 billion (according to McKinsey report), with significant unmet medical needs.

About Hope Medicine

Hope Medicine Inc. is a science-driven clinical-stage biopharmaceutical company with research laboratories and offices in Beijing, Shanghai, and Nanjing, China. HopeMed is established on the in-depth expertise in translational medicine and decades of research of Professor Rui-Ping Xiao's laboratory at the Institute of Molecular Medicine of Peking University. Based on excellent scientific research and to improve the quality of life, HopeMed is committed to the research, development, and commercialization of first-in-class medicines for common and major diseases that threaten human health.

Forward-Looking Statements

This press release contains forward-looking statements that are primarily based on the current outlook, expectations, estimates, and projections of the company's management team. When using "anticipate," "believe," "may," "design," "effect," "assess," "expect," "predict," "target," "aim," "purpose" and any other similar words and expressions, in references to the company, the intention of the statement is forward-looking. Forward-looking statements are not guarantee of future performance and subject to risks and uncertainties, many of which are difficult to predict and often beyond the company's control, which could cause actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; changes in applicable laws or regulations. The company undertakes no public announcement obligation to update or revise any forward-looking statement in this press release, or to publicly announce any such updates or revisions, to reflect changes in our expectations or any events, circumstances or assumptions that affect these statements.

SOURCE Hope Medicine Inc.